Literature DB >> 31700117

LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells.

Zunling Li1,2, Mi Deng2, Fangfang Huang2,3, Changzhu Jin1, Shuang Sun1, Heyu Chen2, Xiaoye Liu2, Licai He2,4, Ali H Sadek2, Cheng Cheng Zhang5.   

Abstract

We recently demonstrated that leukocyte Ig-like receptor 4 (LILRB4) expressed by monocytic acute myeloid leukemia (AML) cells mediates T-cell inhibition and leukemia cell infiltration via its intracellular domain. The cytoplasmic domain of LILRB4 contains three immunoreceptor tyrosine-based inhibitory motifs (ITIMs); the tyrosines at positions 360, 412, and 442 are phosphorylation sites. Here, we analyzed how the ITIMs of LILRB4 in AML cells mediate its function. Our in vitro and in vivo data show that Y412 and Y442, but not Y360, of LILRB4 are required for T-cell inhibition, and all three ITIMs are needed for leukemia cell infiltration. We constructed chimeric proteins containing the extracellular domain of LILRB4 and the intracellular domain of LILRB1 and vice versa. The intracellular domain of LILRB4, but not that of LILRB1, mediates T-cell suppression and AML cell migration. Our studies thus defined the unique signaling roles of LILRB4 ITIMs in AML cells.

Entities:  

Keywords:  AML; ITIM motifs; LILRB4; T cell suppression; infiltration

Mesh:

Substances:

Year:  2019        PMID: 31700117      PMCID: PMC7052276          DOI: 10.1038/s41423-019-0321-2

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  9 in total

1.  eRNAs Identify Immune Microenvironment Patterns and Provide a Novel Prognostic Tool in Acute Myeloid Leukemia.

Authors:  Ziming Jiang; Junyu Long; Kaige Deng; Yongchang Zheng; Miao Chen
Journal:  Front Mol Biosci       Date:  2022-05-02

2.  Th1 responses in vivo require cell-specific provision of OX40L dictated by environmental cues.

Authors:  Dominika W Gajdasik; Fabrina Gaspal; Emily E Halford; Remi Fiancette; Emma E Dutton; Claire Willis; Timo Rückert; Chiara Romagnani; Audrey Gerard; Sarah L Bevington; Andrew S MacDonald; Marina Botto; Timothy Vyse; David R Withers
Journal:  Nat Commun       Date:  2020-07-09       Impact factor: 14.919

3.  TraPS-VarI: Identifying genetic variants altering phosphotyrosine based signalling motifs.

Authors:  Vijay Kumar Ulaganathan
Journal:  Sci Rep       Date:  2020-05-21       Impact factor: 4.379

Review 4.  Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer.

Authors:  Mi Deng; Heyu Chen; Xiaoye Liu; Ryan Huang; Yubo He; Byounggyu Yoo; Jingjing Xie; Samuel John; Ningyan Zhang; Zhiqiang An; Cheng Cheng Zhang
Journal:  Antib Ther       Date:  2021-02-09

5.  Protein Arginine Methyltransferase 5 Promotes the Migration of AML Cells by Regulating the Expression of Leukocyte Immunoglobulin-Like Receptor B4.

Authors:  Lu Zhao; Bingqing Cheng; Jie Xiong; Dan Ma; Xin Liu; Li Wang; Xi Zhang; Jishi Wang
Journal:  Biomed Res Int       Date:  2021-10-19       Impact factor: 3.411

Review 6.  Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy.

Authors:  Calvin D De Louche; Ali Roghanian
Journal:  JCI Insight       Date:  2022-01-25

Review 7.  LILRB4, an immune checkpoint on myeloid cells.

Authors:  Ting Yang; Yixin Qian; Xiaoting Liang; Jianbo Wu; Ming Zou; Mi Deng
Journal:  Blood Sci       Date:  2022-05-17

8.  RelB contributes to the survival, migration and lymphomagenesis of B cells with constitutively active CD40 signaling.

Authors:  Laura B Kuhn; Stefanie Valentin; Kristina Stojanovic; Daniel C Strobl; Tea Babushku; Yan Wang; Ursula Rambold; Laura Scheffler; Sonja Grath; Dorothy John-Robbert; Helmut Blum; Annette Feuchtinger; Andreas Blutke; Falk Weih; Daisuke Kitamura; Roland Rad; Lothar J Strobl; Ursula Zimber-Strobl
Journal:  Front Immunol       Date:  2022-08-30       Impact factor: 8.786

9.  Blocking LAIR1 signaling in immune cells inhibits tumor development.

Authors:  Jingjing Xie; Xun Gui; Mi Deng; Heyu Chen; Yuanzhi Chen; Xiaoye Liu; Zhiqiang Ku; Lingxiao Tan; Ryan Huang; Yubo He; Bruce Zhang; Cheryl Lewis; Kenian Chen; Lin Xu; Jian Xu; Tao Huang; X Charlene Liao; Ningyan Zhang; Zhiqiang An; Cheng Cheng Zhang
Journal:  Front Immunol       Date:  2022-09-21       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.